Case Study 1: Ebola drug discovery
Machine Learning Model to In Vitro Actives
An early success validating our approach was demonstrated for Ebola virus (EBOV). We used public data to generate Bayesian models for the viral pseudotype entry assay and the EBOV replication assay. These models were used to score the MicroSource Spectrum set of 2320 molecules. We selected 3 compounds for testing in vitro. All three were returned as actives.
In Vivo Active
Tilorone was subjected to a time course efficacy study in mice with maEBOV. The two groups given 30 mg/kg tilorone at either 2 or 24 h post-infection both had 100% survival rates with only minimal adverse clinical observations.
Our Ebola work was also the subject of a recent customer story by Biovia.